Literature DB >> 3190503

Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing.

P Trouillas1, F Brudon, P Adeleine.   

Abstract

Some features of cerebellar ataxia have been reported to regress partially with long-term administration of 5-hydroxytryptophan or levorotatory form of 5-hydroxytryptophan. To test this effect further, 30 patients with various inherited or acquired cerebellar ataxias underwent a randomized, double-blind trial of placebo, and the levorotatory form of 5-hydroxytryptophan taken orally for four months. The levorotatory form of 5-hydroxytryptophan significantly improved the ataxia score. It also significantly modified the time of standing upright, the spread of feet, the speed of walking, speaking, and writing. In five cases in which the levorotatory form of 5-hydroxytryptophan therapy was maintained for 12 months, the effect continued progressively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190503     DOI: 10.1001/archneur.1988.00520350055016

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  17 in total

Review 1.  Is the promise of randomized control trials ("evidence-based medicine") overstated?

Authors:  Louis R Caplan
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

2.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 3.  Pharmacological treatments of cerebellar ataxia.

Authors:  Masafumi Ogawa
Journal:  Cerebellum       Date:  2004       Impact factor: 3.847

4.  Buspirone in progressive myoclonus epilepsy.

Authors:  M R Pranzatelli; D Franz; E Tate; J M Martens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

5.  Altered cerebellar organization and function in monoamine oxidase A hypomorphic mice.

Authors:  Loai Alzghoul; Marco Bortolato; Foteini Delis; Panayotis K Thanos; Ryan D Darling; Sean C Godar; Junlin Zhang; Samuel Grant; Gene-Jack Wang; Kimberly L Simpson; Kevin Chen; Nora D Volkow; Rick C S Lin; Jean C Shih
Journal:  Neuropharmacology       Date:  2012-08-16       Impact factor: 5.250

Review 6.  Treatment of cerebellar ataxia with 5-HT1A agonist.

Authors:  Asako Takei; Takeshi Hamada; Ichiro Yabe; Hidenao Sasaki
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

7.  Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.

Authors:  Jacob P R Jacobsen; Adrianna Oh; Rachel Bangle; Wendy L Roberts; Elizabeth L Royer; Nathan Modesto; Sonora A Windermere; Zixuan Yi; Rebecca Vernon; Manuel Cajina; Nikhil M Urs; Joshua C Snyder; Peter J Nicholls; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2019-04-29       Impact factor: 7.853

8.  Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Theresa A Zesiewicz; George Wilmot; Sheng-Han Kuo; Susan Perlman; Patricia E Greenstein; Sarah H Ying; Tetsuo Ashizawa; S H Subramony; Jeremy D Schmahmann; K P Figueroa; Hidehiro Mizusawa; Ludger Schöls; Jessica D Shaw; Richard M Dubinsky; Melissa J Armstrong; Gary S Gronseth; Kelly L Sullivan
Journal:  Neurology       Date:  2018-02-09       Impact factor: 9.910

9.  Continuous subcutaneous lisuride infusion in OPCA.

Authors:  A Heinz; J Wöhrle; L Schöls; P Klotz; W Kuhn; H Przuntek
Journal:  J Neural Transm Gen Sect       Date:  1992

10.  5-HT2A receptor-mediated excitation on cerebellar fastigial nucleus neurons and promotion of motor behaviors in rats.

Authors:  Chang-Zheng Zhang; Qian-Xing Zhuang; Ye-Cheng He; Guang-Ying Li; Jing-Ning Zhu; Jian-Jun Wang
Journal:  Pflugers Arch       Date:  2013-10-22       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.